πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Entrada Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Site-Directed Enzyme Enhancement Therapy platform

Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.

Tags: allosteric regulation, biotechnology, neurological disorders, protein misfolding, rare genetic diseases

Symbol: GANX

Recent Price: $2.18

Industry: Biotechnology

CEO: Mr. Gene Mack M.B.A.

Sector: Healthcare

Employees: 29

Address: 4800 Montgomery Lane, Bethesda, MD 20814

Phone: 301 500 1556

Last updated: 2024-12-31

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. logo
Market Cap: High
Employees: Low

FORCE platform

Dyne Therapeutics, Inc. is a biotechnology company focused on advancing therapeutics for genetically driven muscle diseases, including myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, using its FORCE platform.

Tags: biotechnology, duchenne muscular dystrophy, facioscapulohumeral dystrophy, genetic therapy, muscle diseases, myotonic dystrophy type 1, nucleic acid therapies

Symbol: DYN

Recent Price: $23.65

Industry: Biotechnology

CEO: Mr. John G. Cox M.B.A.

Sector: Healthcare

Employees: 152

Address: 1560 Trapelo Road, Waltham, MA 02451

Phone: 781 786 8230

Last updated: 2024-12-31

Entero Therapeutics, Inc.

Entero Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

latiglutenase

First Wave Bio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and non-systemic therapies for gastrointestinal diseases, including treatments for celiac disease, fat digestion, gastroparesis, and inflammatory bowel diseases.

Tags: biopharmaceutical, celiac disease, gastrointestinal diseases, inflammatory bowel diseases

Symbol: ENTO

Recent Price: $0.62

Industry: Biotechnology

CEO: Mr. James R. Sapirstein M.B.A., R.Ph.

Sector: Healthcare

Employees: 9

Address: 777 Yamato Road, Boca Raton, FL 33431

Phone: (561) 589-7020

Last updated: 2024-12-31

Evelo Biosciences, Inc.

Evelo Biosciences, Inc. logo
Market Cap: Lowest
Employees: Low

EDP1815

Evelo Biosciences, Inc. discovers and develops oral biologics for inflammatory diseases and cancer, with key products like EDP1815 in clinical trials.

Tags: biotechnology, cancer, clinical trials, inflammatory diseases, oral biologics

Symbol: EVLO

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 66

Address: 620 Memorial Drive, Cambridge, MA 02139

Phone: 617 577 0300

Last updated: 2024-12-31

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

ENHANZE drug delivery technology

Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.

Tags: ENHANZE, biologics, biopharma, drug delivery, technology, therapeutics

Symbol: HALO

Recent Price: $47.99

Industry: Biotechnology

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sector: Healthcare

Employees: 373

Address: 11388 Sorrento Valley Road, San Diego, CA 92121

Phone: 858 794 8889

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. logo
Market Cap: High
Employees: Low

EDG-5506

Edgewise Therapeutics, Inc. is a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, including treatments for Duchenne muscular dystrophy and Becker muscular dystrophy.

Tags: Becker muscular dystrophy, Duchenne muscular dystrophy, biopharmaceutical, musculoskeletal diseases, small molecule therapies

Symbol: EWTX

Recent Price: $27.05

Industry: Biotechnology

CEO: Dr. Kevin Koch Ph.D.

Sector: Healthcare

Employees: 97

Address: 3415 Colorado Avenue, Boulder, CO 80303

Phone: 303 735 8373

Leadership

  • Kevin Koch, Ph.D., Director
  • Alan Russell, Ph.D., Director and Co-Founder
  • R. Michael Carruthers, Chief Financial Officer
  • Behrad Derakhshan, Ph.D., Chief Business Officer
  • Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer
  • John Moore, General Counsel
  • Marc Semigran, M.D., Chief Development Officer
  • Peter Thompson, M.D., Chairman and Co-Founder
  • Laura Brege, Director
  • Badreddin Edris, Ph.D., Director and Co-Founder
  • Jonathan C. Fox, M.D., Ph.D., FACC, Director
  • Arlene Morris, Director
  • Jon Root, M.D., Director

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

inupadenant, EOS-448

Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.

Tags: biopharmaceutical, clinical trials, immuno-oncology, therapeutics

Symbol: ITOS

Recent Price: $7.29

Industry: Biotechnology

CEO: Dr. Michel Detheux Ph.D.

Sector: Healthcare

Employees: 157

Address: 321 Arsenal Street, Cambridge, MA 02472-5710

Phone: 339 217 0161

Leadership

  • Michel DETHEUX, President, Chief Executive Officer
  • Matt CALL, Chief Operating Officer
  • Matthew GALL, Chief Financial Officer
  • Yvonne MCGRATH, Chief Scientific Officer
  • David Feltquate, Chief Medical Officer
  • Philippe BRANTEGEM, Executive Vice President of Human Resources
  • Adi OSOVSKY, Executive Vice President of Legal
  • David HALLAL, Chair of the Board
  • Aaron DAVIS,
  • Jill DESIMONE,
  • David LEE,
  • Tim VAN HAUWERMEIREN,
  • Tony HO,
  • Robert IANNONE,
  • Ann RHOADS,

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Onconetix, Inc.

Onconetix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Entadfi

Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing transformative therapies to address global health challenges. The company’s products include Entadfi for benign prostatic hyperplasia and various innovative vaccine candidates.

Tags: Entadfi, biotechnology, healthcare, pharmaceutical, therapies, vaccines

Symbol: ONCO

Recent Price: $0.44

Industry: Biotechnology

CEO: Dr. Ralph Schiess Ph.D.

Sector: Healthcare

Employees: 12

Address: 201 East Fifth Street, Cincinnati, OH 45202

Phone: 513 620 4101

Last updated: 2024-12-31

PepGen Inc.

PepGen Inc. logo
Market Cap: Low
Employees: Low

PGN-EDO51

Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, biotechnology, clinical trials, neuromuscular diseases, oligonucleotide therapeutics

Symbol: PEPG

Recent Price: $3.83

Industry: Biotechnology

CEO: Dr. James G. McArthur Ph.D.

Sector: Healthcare

Employees: 72

Address: 245 Main Street, Cambridge, MA 02142

Phone: 781-797-0979

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

ENTR-601-44

Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.

Tags: Duchenne muscular dystrophy, EEV therapeutics, biotechnology, myotonic dystrophy type 1, neuromuscular diseases

Symbol: TRDA

Recent Price: $17.37

Industry: Biotechnology

CEO: Mr. Dipal Doshi

Sector: Healthcare

Employees: 168

Address: 6 Tide Street, Boston, MA 02210

Phone: 857 520 9158

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31